Skip to content
DoubleBlind·· 11 days agoAI score67

Usona and Compass file new drug applications for psilocybin depression treatments

Will Usona Institute Have the First FDA Approved Psilocybin Drug?

AI summary

DoubleBlind reports that the nonprofit Usona Institute reportedly submitted a NDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary to the FDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary on November 2, 2026 for its synthetic psilocybin candidate for major depressive disorder (MDD), a filing first reported by Psychedelic Alpha that Usona declined to comment on.

Key facts

Compound
Psilocybin
Condition
Depression
Source
DoubleBlind (doubleblindmag.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: DoubleBlind · doubleblindmag.com

Connected to

Compound
Psilocybin
Condition
Depression

Other recent items on these topics